<DOC>
	<DOCNO>NCT02936479</DOCNO>
	<brief_summary>This open-label , single arm trial patient ongoing antibody mediate rejection kidney transplant deem refractory maximal medical therapy give complement inhibitor C1-INH ( Berinert ) effort protect graft ongoing antibody mediate injury . A maximum 5 patient enrol .</brief_summary>
	<brief_title>C1-INH Refractory Antibody Mediated Renal Allograft Rejection</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<criteria>Kidney transplant acute antibody mediate rejection refractory standard therapy Patients know intolerance anaphylaxis Berinert</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>